Results 171 to 180 of about 53,302 (297)

Real‐World Patient Characteristics and Treatment Patterns Among Patients With Interstitial Cystitis (IC)/Bladder Pain Syndrome (BPS)

Reproductive, Female and Child Health, Volume 5, Issue 2, June 2026.
ABSTRACT Objective Interstitial cystitis/bladder pain syndrome (IC/BPS) is linked to bladder and/or pelvic pain, pressure, and discomfort with urinary frequency. Despite guidelines, there is a need for better treatment options. This study analyzed patient demographics, clinical characteristics, and treatment patterns for medications and procedures in ...
Jaromir Mikl, Tiange Yu, Benjamin T. Carter, Andrew Rava, Xin Zhao, Catherine Allende, Amie Devlin, Valentine Pascale, Roger Dmochowski   +8 more
wiley   +1 more source

Efficacy and Short-term Durability of Combined Botulinum Toxin Type A and Rehabilitation for Chronic Facial Asymmetry After Facial Nerve Palsy. [PDF]

Plast Reconstr Surg Glob Open
Yamashita A, Miyanaga T, Yamashita M.
europepmc   +1 more source

Emerging Treatments for Erectile Dysfunction

Trends in Urology &Men's Health, Volume 17, Issue 3, June 2026.
ABSTRACT Erectile dysfunction (ED) is a prevalent condition that can significantly affect men's sexual health and quality of life, and for which there are many well‐studied effective treatments. In spite of this, many individuals still seek out alternative therapies.
Resa Magill, Jeff Morrison, Juan Andino, Jasper Bash   +3 more
wiley   +1 more source

Intravesical Botulinum Toxin Type A for an Overactive Bladder: A Single-Center Audit. [PDF]

Cureus
Abolanle P, Richards TM, Eylert M, Saunders R, Hussain P, Seymour C.   +5 more
europepmc   +1 more source

Altered cytoskeletal integrity underlies impaired platelet shape change and defective thrombus formation in ETV6‐related thrombocytopenia

British Journal of Haematology, Volume 208, Issue 6, Page 1965-1979, June 2026.
Summary ETV6‐related thrombocytopenia (ETV6‐RT) is an inherited platelet disorder caused by germline ETV6 variants. Despite recent progress, the mechanisms underlying platelet dysfunction in ETV6‐RT remain unclear. We investigated 12 patients from six families using functional assays, electron microscopy, quantitative proteomics and cytoskeletal ...
Ivan P. Tesakov, Julia‐Jessica D. Korobkin, Daria V. Fedorova, Sofia V. Galkina, Maria M. Golomysova, Sergei I. Obydennyi, Anastasia A. Ignatova, Ekaterina‐Iva A. Adamanskaya, Eugenia V. Yushkova, Anna V. Pavlova, Pavel A. Zharkov, Igor I. Kireev, Galina A. Novichkova, Viktor G. Zgoda, Mikhail A. Panteleev, Anastasia N. Sveshnikova   +15 more
wiley   +1 more source

Why, When, and How to Treat Dynamic Forehead Lines with Botulinum Toxin Type A. [PDF]

Toxins (Basel)
de Sanctis Pecora C, Kerscher M, Muniz M, Trindade de Almeida A.   +3 more
europepmc   +1 more source

Paralysis of the orbicularis muscle of the eye using botulinum toxin type A in the treatment for dry eye

Acta ophthalmologica, 2017
J. Serna-Ojeda, Á. Nava-Castañeda
semanticscholar   +1 more source

Three‐year outcomes of repeated botulinum neurotoxin A injections to the lower extremities in young children with spastic cerebral palsy in GMFCS levels I to III

Developmental Medicine &Child Neurology, Volume 68, Issue 6, Page 792-799, June 2026.
In this study, we followed a group of children 2 to 6 years old with spastic cerebral palsy functioning in GMFCS levels I–III, over 3 years. Sixty‐five received BoNT‐A and 59 did not. Repeated BoNT‐A injections over 3 years were not associated with improvements in gross motor function or passive ankle dorsiflexion. Daily step counts, favouring the BoNT‐
Darcy Fehlings, Emma Bohn, Lauren Switzer, Charles H. Goldsmith, Unni Narayanan, Peter L. Rosenbaum, F. Virginia Wright, Gary Foster, CP‐BoNT‐A Study Group, Timothy Carey, Mark Mason, Ronit Mesterman   +11 more
wiley   +1 more source

Comparative Analytics and Pharmacodynamics of the Complex Protein-Free Botulinum Toxin Type A Formulations DaxibotulinumtoxinA, IncobotulinumtoxinA and RelabotulinumtoxinA. [PDF]

Toxins (Basel)
Honndorf S, Kühbach K, Eisele KH, Shokurova A, Buch P, Jatzke C, Taylor HV, Fink K.   +7 more
europepmc   +1 more source

Botulinum Toxin Type A for Pain in Advanced Parkinson’s Disease

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2017
V. Bruno, M. Freitas, D. Mancini, Jane P Lui, J. Miyasaki, S. Fox   +5 more
semanticscholar   +1 more source